Key Highlights

● IDNA fell 2.71% to $40.91 in Friday's October 16 intraday session.

● IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index.

● The fund holds roughly 45 to 55 biotechnology and pharmaceutical equities worldwide.

● IDNA charges a 0.47% expense ratio and showed a 30-day SEC yield near 0.66%.

iShares Genomics Immunology and Healthcare ETF (NYSE American:IDNA) fell 2.71% to $40.91 in intraday trading on Friday, October 16. IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index.

While conventional healthcare exchange-traded funds such as XLV are heavily weighted in mature pharmaceutical conglomerates and health insurance providers, the frontier of medical innovation has shifted toward living cellular drugs and targeted immunotherapies that harness the human immune system to destroy malignant tumors. IDNA delivers focused, global exposure to this scientific revolution, investing across biotechnology companies engaged in gene editing, immunology, and bio-engineering.

International precision medicine has attracted significant capital: breakthrough regulatory approvals for CRISPR therapies, personalized cancer vaccines, and antibody-drug conjugates (ADCs) have established viable commercial markets for next-generation biotechnology platforms.

Legal Architecture & FactSet Benchmark Index Rules

IDNA is registered under the Investment Company Act of 1940 as an open-end management investment company, operating as an active investment series of the iShares Trust. BlackRock Fund Advisors serves as the registered investment advisor, overseeing index replication, overseas custody, and portfolio rebalancing. The fund launched in June 2019.

The fund tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. This rules-based benchmark screens developed and emerging market equities to identify corporations deriving material revenue from genomics, immuno-oncology, gene therapy, and bio-engineering. The index enforces strict liquidity filters and a modified equal-weighting methodology at semi-annual reconstitutions, ensuring that mid-cap clinical innovators receive meaningful portfolio weighting.

Portfolio Composition: Global Biopharmaceutical Breadth

IDNA holds approximately 45 to 55 international biotechnology and pharmaceutical equities across the United States, Europe, and Asia. This geographic diversity distinguishes IDNA from US-centric healthcare funds.

Its top portfolio holdings include commercial biotechnology pioneers Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX), immuno-oncology leaders Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX), gene editing champions CRISPR Therapeutics (NASDAQ:CRSP) and Alnylam Pharmaceuticals (NASDAQ:ALNY), alongside specialized European pharmaceutical giants like AstraZeneca, Novartis (NYSE:NVS), and Sanofi (NASDAQ:SNY). This composition ensures that IDNA balances high-growth clinical-stage innovators with mature biopharmaceutical giants possessing massive global commercial distribution networks.

Cost Structure, Operating Expense Ratio & Yield Realities

BlackRock (NYSE:BLK) charges a competitive annual management expense ratio of 0.47% for IDNA. Compared to specialized actively managed biotech funds that frequently charge 0.75% or more, IDNA provides cost-efficient global exposure to genomics and immunology.

The fund maintains a modest income profile, distributing dividends semi-annually with a 30-day SEC yield of approximately 0.66% as of October 2026, supported by cash distributions from mature European pharmaceutical constituents.

Performance Dissection: Clinical Breakthroughs & Pipeline Commercialization

In intraday trading on Friday, October 16, IDNA opened at $42.27 and traded between $40.75 and $42.27, compared with a previous close of $42.05. The fund's 52-week range of $24.29 to $43.44 reflects a rebound driven by a wave of clinical trial successes and accelerated commercial adoption of precision antibody-drug conjugates and cell therapies.

Furthermore, major pharmaceutical corporations facing patent expirations on legacy blockbuster drugs initiated aggressive mergers and acquisitions, acquiring innovative clinical-stage genomics firms at substantial premiums, delivering powerful equity alpha across the portfolio.

Distribution Profile, Foreign Tax Withholding & Form 1099 Reporting

IDNA provides standard Form 1099-DIV reporting to shareholders. Distributions generally qualify as qualified dividend income (QDI) for eligible US investors, and the fund completely avoids the administrative burdens of Schedule K-1 partnership tax forms.

Furthermore, because the fund holds foreign pharmaceutical equities in Europe and Asia, BlackRock reports foreign tax credits, enabling US taxable investors to recover foreign dividend withholding taxes on their annual federal tax filings.

Secondary Market Liquidity & Lead Market Making

Trading under the ticker IDNA, the fund benefits from active secondary market liquidity supported by lead market makers and institutional authorized participants. Intraday bid-ask spreads typically hover between three and five cents per share during normal US trading hours.

Because underlying portfolio holdings trade on deep US and European exchanges with multi-billion-dollar liquidity, authorized participants execute block creation and redemption trades with minimal pricing slippage relative to net asset value.

Primary Investment Risks: Clinical Failures & Regulatory Scrutiny

Investing in IDNA involves significant sector and scientific risks. Biopharmaceutical development is characterized by high clinical attrition: unexpected safety signals or efficacy failures in Phase 3 clinical trials can cause individual holdings to lose substantial market value.

Additionally, pharmaceutical pricing legislation in the United States and international healthcare cost-containment policies present continuous regulatory headwinds. The fund also remains sensitive to broader biotechnology equity funding cycles and interest rate volatility.

Gene Therapy Reach Across Three Regions

IDNA spreads roughly 45 to 55 stocks across the United States, Europe, and Asia, pairing clinical-stage innovators such as CRISPR Therapeutics and Moderna with established companies including Novartis and Sanofi.

Because the fund holds foreign pharmaceutical equities, BlackRock reports foreign tax credits that let US taxable investors recover dividend withholding taxes.